Next Article in Journal
A Comparative Proteomic Analysis of Pinellia ternata Leaves Exposed to Heat Stress
Next Article in Special Issue
Protein Glutathionylation in Cardiovascular Diseases
Previous Article in Journal
Structural Insights into a Novel Interkingdom Signaling Circuit by Cartography of the Ligand-Binding Sites of the Homologous Quorum Sensing LuxR-Family
Previous Article in Special Issue
Proteomic Analysis Identifies an NADPH Oxidase 1 (Nox1)-Mediated Role for Actin-Related Protein 2/3 Complex Subunit 2 (ARPC2) in Promoting Smooth Muscle Cell Migration
Open AccessReview

The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease

1
Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA
2
Veterans Affairs Medical Center, Iowa City, IA 52242, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2013, 14(10), 20597-20613; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms141020597
Received: 24 July 2013 / Revised: 20 September 2013 / Accepted: 8 October 2013 / Published: 15 October 2013
(This article belongs to the Special Issue Oxidative Stress in Cardiovascular Disease)
The epidermal growth factor receptor (EGFR) family and its ligands serve as a switchboard for the regulation of multiple cellular processes. While it is clear that EGFR activity is essential for normal cardiac development, its function in the vasculature and its role in cardiovascular disease are only beginning to be elucidated. In the blood vessel, endothelial cells and smooth muscle cells are both a source and a target of EGF-like ligands. Activation of EGFR has been implicated in blood pressure regulation, endothelial dysfunction, neointimal hyperplasia, atherogenesis, and cardiac remodeling. Furthermore, increased circulating EGF-like ligands may mediate accelerated vascular disease associated with chronic inflammation. Although EGFR inhibitors are currently being used clinically for the treatment of cancer, additional studies are necessary to determine whether abrogation of EGFR signaling is a potential strategy for the treatment of cardiovascular disease. View Full-Text
Keywords: EGFR; EGF-like ligands; vascular disease; atherosclerosis; cardiac remodeling EGFR; EGF-like ligands; vascular disease; atherosclerosis; cardiac remodeling
Show Figures

Graphical abstract

MDPI and ACS Style

Makki, N.; Thiel, K.W.; Miller, F.J., Jr. The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease. Int. J. Mol. Sci. 2013, 14, 20597-20613. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms141020597

AMA Style

Makki N, Thiel KW, Miller FJ Jr.. The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease. International Journal of Molecular Sciences. 2013; 14(10):20597-20613. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms141020597

Chicago/Turabian Style

Makki, Nader; Thiel, Kristina W.; Miller, Francis J., Jr. 2013. "The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease" Int. J. Mol. Sci. 14, no. 10: 20597-20613. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms141020597

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop